ACAD Insider Trading
Insider Ownership Percentage: 26.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,521,596.85
ACADIA Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at ACADIA Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
ACADIA Pharmaceuticals Share Price & Price History
Current Price: $17.45
Price Change: ▲ Price Increase of +0.285 (1.66%)
As of 05/15/2025 03:41 PM ET
ACADIA Pharmaceuticals Insider Trading History
SEC Filings (Institutional Ownership Changes) for ACADIA Pharmaceuticals (NASDAQ:ACAD)
96.71% of ACADIA Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at ACAD by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
ACADIA Pharmaceuticals Institutional Trading History
Data available starting January 2016
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Read More on ACADIA Pharmaceuticals
Today's Range
Now: $17.45
52 Week Range
Now: $17.45
Volume
801,752 shs
Average Volume
1,849,174 shs
Market Capitalization
$2.92 billion
P/E Ratio
22.35
Dividend Yield
N/A
Beta
0.47
Who are the company insiders with the largest holdings of ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' top insider investors include:
- Bros Advisors Lp Baker (Director)
- Stephen Davis (CEO)
- Mark C Schneyer (EVP)
- Brendan Teehan (COO)
- Mark C Schneyer (CFO)
- Austin D Kim (EVP)
- James Kihara (Insider)
- Elizabeth A Garofalo (Director)
- Laura Brege (Director)
Learn More about top insider investors at ACADIA Pharmaceuticals.
Who are the major institutional investors of ACADIA Pharmaceuticals?
Which institutional investors are selling ACADIA Pharmaceuticals stock?
In the last quarter, ACAD stock was sold by these institutional investors:
- SG Americas Securities LLC
- Canada Pension Plan Investment Board
- Capital Fund Management S.A.
- Deutsche Bank AG
- Trexquant Investment LP
- Algert Global LLC
- Walleye Capital LLC
- Connor Clark & Lunn Investment Management Ltd.
During the previous year, company insiders that have sold ACADIA Pharmaceuticals company stock include:
- Bros Advisors Lp Baker (Director)
- Stephen Davis (CEO)
- Mark C Schneyer (EVP)
- Brendan Teehan (COO)
- Mark C Schneyer (CFO)
- Austin D Kim (EVP)
Learn More investors selling ACADIA Pharmaceuticals stock.
Which institutional investors are buying ACADIA Pharmaceuticals stock?
During the previous quarter, ACAD stock was purchased by institutional investors including:
- Assenagon Asset Management S.A.
- American Century Companies Inc.
- Nuveen LLC
- Vanguard Group Inc.
- Principal Financial Group Inc.
- Jupiter Asset Management Ltd.
- Bank of New York Mellon Corp
- Public Sector Pension Investment Board